Clinical trials
IgA Nephropathy (IgAN) clinical trials
Below are recruiting iga nephropathy (igan) clinical trials, each written for real people, not researchers. We’re tracking 49 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07146906RecruitingPhase 2
Study of zigakibart for IgA nephropathy
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
Denver, ColoradoAges 18–100 - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT05234463Recruiting
Study links complement activity to IgA kidney disease severity
This study looks at how parts of the immune system (called complement) may relate to how severe IgA kidney disease is. It may help doctors understand disease activity better, even if the study is mainly observational.
StrasbourgAges 18 years+ - NCT05190848Recruiting
Study of gut microbes and blood chemicals in IgA kidney disease
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
Guangzhou, GuangdongAges 16–65 - NCT06654596Recruiting
Telitacicept for IgA nephropathy
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
ShanghaiAges 18–70 - NCT06676007Recruiting
Early use of a targeted budesonide for IgA nephropathy
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Chengdu, SichuanAges 18–75 - NCT06676384RecruitingPhase 4
Testing additional drugs for IgA nephropathy in South Asian patients
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Nadiād, GujaratAges 18–65 - NCT06676579RecruitingPhase 2
Avacopan for active IgA kidney disease with crescents
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
Jacksonville, FloridaAges 18 years+ - NCT06712407RecruitingPhase 4
Extended TARPEYO treatment for IgA nephropathy
This study tests whether taking TARPEYO (budesonide) for longer than 9 months is safe and effective for adults with IgA nephropathy. It's for people who have already completed a 9-month course of TARPEYO and are on stable blood pressure medication.
Birmingham, AlabamaAges 18 years+ - NCT06760845Recruiting
Using light to diagnose kidney disease
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Jinan, ShandongAges Any age - NCT06819826RecruitingPhase 3
Study of SC0062 for IgA Nephropathy with Proteinuria
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
Guangzhou, Yuexiu DistrictAges 18 years+ - NCT06926244Recruiting
Studying resistance to IgA nephropathy treatments in real life
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
ParisAges 18 years+ - NCT07054684RecruitingPhase 1
Study of BHV-1400 for IgA Nephropathy
This trial tests a new medicine, BHV-1400, for people with IgA Nephropathy, a kidney disease. The goal is to see if it can help slow down kidney damage.
Farmington, ConnecticutAges 18–65 - NCT07056595Recruiting
Finerenone for IgA nephropathy patients
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
MoscowAges 18 years+ - NCT07305974RecruitingPhase 2
Study of RG002C0106 for primary IgA nephropathy
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Beijing, Beijing MunicipalityAges 18–65 - NCT07390123RecruitingPhase 3
Study of HSK39297 for IgA Nephropathy (IgAN)
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Huangshan City, AnhuiAges 18 years+ - NCT07616700RecruitingPhase 2
Long-term safety study of HSK39297 for IgA kidney disease
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
BeijingAges Any age - NCT04858724Recruiting
IgA nephropathy patient registry for long-term outcomes
This study gathers information from people with IgA nephropathy to better understand how the disease changes over time and what can be expected. The goal is to improve care and help guide future treatments.
Shanghai, Shanghai MunicipalityAges Any age - NCT07354932RecruitingPhase 2
Testing SHR-2173 for IgA Nephropathy
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
Guangzhou, GuangdongAges 18 years+ - NCT07498673RecruitingEarly Phase 1
Testing YKST02 for IgA nephropathy
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
Wuhan, HubeiAges 18–75 - NCT06989359RecruitingPhase 2
Study of ADX-038 for complement-related kidney disease
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
Doral, FloridaAges 18 years+ - NCT06935357RecruitingPhase 3
Felzartamab infusions for IgA nephropathy
This study tests a new drug called Felzartamab (given as an infusion) for people with IgA nephropathy (IgAN), a kidney disease. The goal is to see if it can reduce protein leaking into urine and protect kidney function.
Little Rock, ArkansasAges 18 years+ - NCT07074951Recruiting
Tonsillectomy and immune therapy for high-risk IgA kidney disease
This trial tests whether removing the tonsils (tonsillectomy) plus immune-suppressing therapy can help people with a high-risk form of IgA nephropathy, a kidney disease. It aims to slow down kidney damage and delay the need for dialysis.
Saint PetersburgAges 18–75 - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Woolloongabba, QueenslandAges 18 years+
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for iga nephropathy (igan)?
- Yes. Clin2 currently lists 49 recruiting iga nephropathy (igan) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a iga nephropathy (igan) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a iga nephropathy (igan) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.